// App-Quantinova.ai

TPS2592 : A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors.

Researchers

Presenter

  • Kenji Hashimoto

Principal Investigators

  • Ayesh Perera

  • Yoshitaka Ogita

  • Mikiko Nakamura

  • Takahiro Ishiguro

  • Yuji Sano

  • Yasuko Kinoshita

  • Mika Kamata Sakurai

  • Werner Frings

  • Shun-ichiro Komatsu

  • Akihisa Kaneko

  • Masamichi Ueda

  • Shohei Kishishita

  • Athos Gianella-Borradori

Medical Centers

  • Chugai Pharma Europe, London, United Kingdom

  • Chugai Pharma Europe, London, United Kingdom

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Chugai Kamakura Research Laboratories, Kamakura, Japan

  • Chugai Fuji Gotemba Research Laboratories, Gotemba, Japan

  • Chugai Fuji Gotemba Research Laboratories, Gotemba, Japan

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Chugai Pharma USA, Barkeley Heights, NJ

Locations

  • United States

  • United Kingdom

  • Japan

Companies

  • Chugai Pharma UK Ltd

  • Chugai Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Glypican-3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Expansion Study

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved